title: Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials.
authors.affiliation: Baylor University Medical Center, Dallas, TX. goran.klintmalm@BSWHealth.org.
authors.forename: G B
authors.initials: GB
authors.lastname: Klintmalm
authors.affiliation: University of California San Francisco, San Francisco, CA.
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.affiliation: Duke University, Durham, NC.
authors.forename: A
authors.initials: A
authors.lastname: Kirk
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D000208:Acute Disease; D023381:Endpoint Determination; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney; D016030:Kidney Transplantation
chemical_list: D007166:Immunosuppressive Agents; D000069594:Abatacept
keywords: clinical trial design; editorial/personal viewpoint; guidelines; immunosuppressant; immunosuppression/immune modulation